DALIAN BIO-CHEM COMPANY LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.03 CNY | +10.01% |
|
+14.45% | +61.12% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 6,528 | 3,988 | 3,334 | 6,013 | - |
| Enterprise Value (EV) 1 | 6,528 | 3,988 | 3,334 | 6,013 | 6,013 |
| P/E ratio | 21.3 x | 18 x | 13.2 x | 14.4 x | 12.6 x |
| Yield | 1.72% | - | - | - | - |
| Capitalization / Revenue | 7.49 x | - | - | 4.66 x | 3.99 x |
| EV / Revenue | 7.49 x | - | - | 4.66 x | 3.99 x |
| EV / EBITDA | 16.5 x | - | - | 12.9 x | 11.4 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | 6.32 x | - | - | 1.96 x | 1.61 x |
| Nbr of stocks (in thousands) | 365,885 | 365,885 | 357,980 | 353,067 | - |
| Reference price 2 | 17.84 | 10.90 | 9.314 | 17.03 | 17.03 |
| Announcement Date | 3/19/20 | 3/30/21 | 4/25/22 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 871.9 | - | - | 1,291 | 1,508 |
| EBITDA 1 | 394.5 | - | - | 466 | 529 |
| EBIT 1 | 367.5 | - | - | 491 | 563 |
| Operating Margin | 42.15% | - | - | 38.03% | 37.33% |
| Earnings before Tax (EBT) 1 | 367.4 | - | - | 491 | 563 |
| Net income 1 | 306.8 | 221.8 | 250.5 | 424 | 486 |
| Net margin | 35.19% | - | - | 32.84% | 32.23% |
| EPS 2 | 0.8367 | 0.6071 | 0.7071 | 1.180 | 1.350 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | 0.3061 | - | - | - | - |
| Announcement Date | 3/19/20 | 3/30/21 | 4/25/22 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 Q3 |
|---|---|---|
| Net sales 1 | - | 343.6 |
| EBITDA | - | - |
| EBIT | - | - |
| Operating Margin | - | - |
| Earnings before Tax (EBT) | - | - |
| Net income | 227.6 | - |
| Net margin | - | - |
| EPS 2 | 0.6500 | 0.3071 |
| Dividend per Share | - | - |
| Announcement Date | 8/15/22 | 10/28/22 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 33.5% | - | - | 18.8% | 17.8% |
| ROA (Net income/ Total Assets) | 29.4% | - | - | 16.7% | 15.9% |
| Assets 1 | 1,043 | - | - | 2,539 | 3,057 |
| Book Value Per Share 2 | 2.820 | - | - | 8.690 | 10.60 |
| Cash Flow per Share 2 | 0.6600 | - | - | 1.470 | 1.710 |
| Capex | 62.9 | - | - | - | - |
| Capex / Sales | 7.21% | - | - | - | - |
| Announcement Date | 3/19/20 | 3/30/21 | 4/25/22 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
17.03
CNY
Average target price
17.7
CNY
Spread / Average Target
+3.93%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +61.12% | 831M | |
| +4.64% | 105B | |
| -6.47% | 62.52B | |
| +72.86% | 49.08B | |
| +16.94% | 38.99B | |
| +5.28% | 32.59B | |
| +14.48% | 20.6B | |
| +15.10% | 17.19B | |
| +18.07% | 15.13B | |
| +4.83% | 14.36B |
- Stock Market
- Equities
- 603360 Stock
- Financials Dalian BIO-CHEM Company Limited